Dr. O'Neil on Next Steps for Napabucasin With FOLFIRI and Bevacizumab in CRC
Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the next steps for napabucasin with FOLFIRI and bevacizumab (Avastin) as treatment for patients with colorectal cancer.
Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the next steps for napabucasin with FOLFIRI and bevacizumab (Avastin) as treatment for patients with colorectal cancer (CRC).
A study of napabucasin with FOLFIRI and bevacizumab showed that napabucasin could be given orally at 240 mg twice daily along with a full dose of FOLFIRI.
In addition to a phase III trial that randomizes patients to either FOLFIRI or FOLFIRI plus napabucasin, the cohort of patients who were refractory to prior irinotecan was expanded. This is to confirm that the response to combination napabucasin plus FOLFIRI and bevacizumab is durable.
